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7LETTER TO THE EDITOR
evimeline Reduced Mouth Dryness and Increased
alivary Flow in Patients with Xerostomia
omplicating Chronic Graft-versus-Host Disease
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1The mouth is affected in 75% to 85% of patients
ith chronic graft-versus-host disease (cGVHD) after
llogeneic hematopoietic cell transplantation and ranks
econd behind the skin in order of prevalence of organ
nvolvement [1]. Labial salivary gland biopsies show
vidence of immunologically mediated destruction with
ymphocytic inﬁltration [2]. Patients with cGVHD of
he mouth frequently have xerostomia, which can be a
istressing condition causing taste alterations, difﬁ-
ulty with chewing and swallowing, and anorexia, all
otentially contributing to nutritional deﬁcits and un-
esired weight loss [3,4]. In addition, the oral mucosa
ecomes susceptible to infection by Candida albicans,
nd overgrowth of procariogenic bacteria accelerates
ental decay [5]. Xerostomia may have a greater effect
or patients with cGVHD because of additional oral
omplications such as lichenoid and hyperkeratotic
ucosal lesions, pseudomembranes, ulcers, and infec-
ions [6].
The Ancillary and Supportive Care Working
roup of the National Institutes of Health Consen-
us Development Project on Criteria for Clinical
rials in cGVHD has concluded that the procho-
inergic agents pilocarpine and cevimeline, which
re approved for symptomatic treatment of xerosto-
ia associated with Sjögren syndrome, can be con-
idered optional therapy for cGVHD-associated xe-
ostomia [7]. In a small open-label, uncontrolled
tudy, treatment with pilocarpine signiﬁcantly im-
roved objective and subjective measurements of
alivary function in 6 patients with cGVHD-related
erostomia [8]. The relative selectivity of cevime-
ine for the M1 and M3 muscarinic receptors [9]
ay make it a preferred agent for use in patients
ith cGVHD.
Three patients at the Fred Hutchinson Cancer
esearch Center, Seattle, were enrolled in an open-
abel trial of cevimeline for cGVHD-associated xe-
ostomia and completed treatment before the trial’s
remature termination due to slow accrual. The
rimary outcome measurement was the patient’s
nal global evaluation of xerostomia as better, much
etter, worse, much worse, or unchanged after 10
92eeks of treatment. Secondary outcome measure-
ents included the patient’s evaluation of separate
ymptoms using a 100-mm visual analog scale and
nstimulated salivary ﬂow 1.5 to 2.5 hours after the
dministration of a dose of cevimeline. Cevimeline
as given at a dosage of 15 mg 3 times a day for 2
eeks, then 30 mg 3 times a day, and then 45 mg 3
imes a day for the ﬁnal 4 weeks of the study, if no
mprovement and no dose-limiting toxicity were
een at the end of week 6.
The experience of these 3 patients (Table 1),
ho each had persistent xerostomia symptoms de-
pite an adequate trial of altered systemic or topical
mmunosuppressive therapy, indicates that cevime-
ine may be a useful ancillary therapy for xerostomia
ssociated with cGVHD. All 3 patients reported
mprovement in the global evaluation of dry mouth,
nd 2 had increased unstimulated salivary ﬂow after
0 weeks of treatment. In 1 patient, clinically sig-
iﬁcant and probably treatment-related adverse
vents developed on the last day of the 10-week
tudy period. Symptoms of wheezing and eye dis-
omfort may have been attributable to excessive
ystemic cholinergic effects at the highest dosage.
o clinically signiﬁcant abnormalities in vital signs,
lectrocardiograms, or laboratory values were de-
ected during treatment with cevimeline.
The experience of these 3 patients conﬁrms the
otential beneﬁt of cevimeline for treating cGVHD-
ssociated xerostomia, and we recommend the stan-
ard approved dosage of 30 mg 3 times a day. Larger
tudies are warranted to conﬁrm efﬁcacy and safety in
his population.
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able 1. Characteristics and Responses of the 3 Study Participants*
Characteristics Patient 1
ender Male
iagnosis MDS
aseline demographics
Age at study entry (y) 57
Duration of cGVHD (mo) 4
Prior sites of cGVHD Skin, mouth
Oral mucosal exam
Erythema Yes
Atrophy Yes
Lichenoid striae Yes
Hyperkeratotic plaques Yes
Extensive dental caries Yes
Saliva Visibly reduced
Prior therapies (duration)
First P  CSP (6 wk)
Second P  CSP  oral AZA o
DEXA rinses (6 mo)
Third P  TAC  SIR (6 wk
evimeline therapy†
Days 1-14 15
Days 15-42 30
Days 43-70 30
lobal xerostomia evaluation
Day 14 Better
Day 42 Much better
Day 70 Much better
nstimulated salivary flow (g)‡
Baseline 3.87
Day 14 6.66
Day 42 8.88
Day 70 11.21
erosis questionnaire (day 70)
Ability to speak without drinking
liquids improved
Yes
Fluid intake frequency decreased Yes
Chewing improved Yes
Swallowing improved Yes
Broadened food choices Yes
Decreased oral sensitivities Yes
Decreased mouth sores Yes
Improved sleep Yes
Decreased use of AT Yes
omments Dry mouth recurred
immediately after stud
ended; cevimeline was
then resumed for anoth
2 y
AML indicates acute myelogenous leukemia; AT, artiﬁcial tears
myelodysplastic syndrome; P, prednisone; SIR, sirolimus; TAC
Milligrams, oral, 3 times daily.
Amount of saliva collected over a period of 6 minutes.. Lenssen P, Sherry ME, Cheney CL, et al. Prevalence of nutri-tion-related problems among long-term survivors of allogeneic
marrow transplantation. J Am Diet Assoc. 1990;90:835-842.
. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition
and treatment. J Am Dent Assoc. 2003;134:61-69.
. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host
Data
Patient 2 Patient 3
Male Male
AML AML
25 47
84 12
Skin, eyes, mouth Skin, eyes, mouth, gut
Yes Yes
Yes Yes
Yes Yes
No Yes
No No
Scant and foamy Visibly reduced
P  CSP (18 mo) P  CSP (12 mo)
None (lost to follow-up for 2 y) P  CSP, oxycodone 
paroxetine (4 mo)
CSP and AT (7 wk) None
15 15
30 30
45 30
No change Better
Better Better
Better Much better
1.56 0.32
1.51 0.95
1.38 1.28
1.32 1.77
Yes Yes
No No
Yes Yes
Yes Yes
— —
Yes —
— —
Unchanged Yes (but variable)
Yes —
Wheezing and eye discomfort
at day 70 resolved when
cevimeline stopped, but
xerostomia recurred
Dry mouth recurred after
study ended; patient was
treated with a short
course of oral DEXA
rinses and resumed
cevimeline for several
months
azathioprine; CSP, cyclosporine; DEXA, dexamethasone; MDS,
imus.r
)
y
er
; AZA,
, tacroldisease. Biol Blood Marrow Transplant. 2003;9:215-233.
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